Abstract
We present the SAR study that led us to identification of the first inhibitors of type 7 17β- hydroxysteroid dehydrogenase (17β-HSD). The conversion of E1 into E2 is reduced by nearly 90 % by 17β-(Nalkylformamido)- 4-methyl-4-aza-5α-androstan-3-one compounds bearing a side chain containing 7 to 10 carbon atoms when tested at 0.3 μM.
Keywords: enzyme, hydroxysteroid dehydrogenase, 4-aza-steroids, sar, inhibitors, steroidogenesis
Letters in Drug Design & Discovery
Title: First Inhibitors of the Steroidogenic Enzyme Type 7 17β-Hydroxysteroid Dehydrogenase
Volume: 1 Issue: 3
Author(s): E. Bellavance, V. Luu-The and D. Poirier
Affiliation:
Keywords: enzyme, hydroxysteroid dehydrogenase, 4-aza-steroids, sar, inhibitors, steroidogenesis
Abstract: We present the SAR study that led us to identification of the first inhibitors of type 7 17β- hydroxysteroid dehydrogenase (17β-HSD). The conversion of E1 into E2 is reduced by nearly 90 % by 17β-(Nalkylformamido)- 4-methyl-4-aza-5α-androstan-3-one compounds bearing a side chain containing 7 to 10 carbon atoms when tested at 0.3 μM.
Export Options
About this article
Cite this article as:
Bellavance E., Luu-The V. and Poirier D., First Inhibitors of the Steroidogenic Enzyme Type 7 17β-Hydroxysteroid Dehydrogenase, Letters in Drug Design & Discovery 2004; 1 (3) . https://dx.doi.org/10.2174/1570180043398867
DOI https://dx.doi.org/10.2174/1570180043398867 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design Benzimidazole Derivatives as Kinase Inhibitors
Current Medicinal Chemistry E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Research Progress on the Mechanisms of Combined Bevacizumab and Radiotherapy
Recent Patents on Anti-Cancer Drug Discovery Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Radiopharmaceutical Tracking of Particles Injected into Tumors: A Model to Study Clearance Kinetics
Current Drug Delivery Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Current Drug Targets Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Alphavirus Vectors for Gene Therapy Applications
Current Gene Therapy A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters Novel Subtype Specific and Universal Somatostatin Analogues: Clinical Potential and Pitfalls
Current Pharmaceutical Design Molecular Basis of Therapeutic Strategies for Breast Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Do Insecticides have Adverse Effects on Reproduction
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Identification of Potential MEK1 Inhibitors by Pharmacophore-based Virtual Screening and MD Simulations
Letters in Drug Design & Discovery Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway
Current Cancer Drug Targets